Merck
CN
  • A novel approach to a fine particle coating using porous spherical silica as core particles.

A novel approach to a fine particle coating using porous spherical silica as core particles.

Drug development and industrial pharmacy (2013-06-21)
Makoto Ishida, Jumpei Uchiyama, Keiko Isaji, Yuta Suzuki, Yasuyuki Ikematsu, Shigeru Aoki
摘要

Abstract The applicability of porous spherical silica (PSS) was evaluated as core particles for pharmaceutical products by comparing it with commercial core particles such as mannitol (NP-108), sucrose and microcrystalline cellulose spheres. We investigated the physical properties of core particles, such as particle size distribution, flow properties, crushing strength, plastic limit, drying rate, hygroscopic property and aggregation degree. It was found that PSS was a core particle of small particle size, low friability, high water adsorption capacity, rapid drying rate and lower occurrence of particle aggregation, although wettability is a factor to be carefully considered. The aggregation and taste-masking ability using PSS and NP-108 as core particles were evaluated at a fluidized-bed coating process. The functional coating under the excess spray rate shows different aggregation trends and dissolution profiles between PSS and NP-108; thereby, exhibiting the formation of uniform coating under the excess spray rate in the case of PSS. This expands the range of the acceptable spray feed rates to coat fine particles, and indicates the possibility of decreasing the coating time. The results obtained in this study suggested that the core particle, which has a property like that of PSS, was useful in overcoming such disadvantages as large particle size, which feels gritty in oral cavity; particle aggregation; and the long coating time of the particle coating process. These results will enable the practical fine particle coating method by increasing the range of optimum coating conditions and decreasing the coating time in fluidized bed technology.

材料
货号
品牌
产品描述

Sigma-Aldrich
甲基丙烯酸甲酯, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
2-(二甲氨基)甲基丙烯酸乙酯, contains 700-1000 ppm monomethyl ether hydroquinone as inhibitor, 98%
Sigma-Aldrich
甲基丙烯酸丁酯, 99%, contains monomethyl ether hydroquinone as inhibitor
Sigma-Aldrich
硬脂酸镁, technical grade
Sigma-Aldrich
甲基丙烯酸甲酯, 99%, stabilized
Sigma-Aldrich
柠檬酸三乙酯, ≥98.0% (GC)
Sigma-Aldrich
柠檬酸三乙酯, ≥99%, FCC, FG
Supelco
柠檬酸三乙酯, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
硬脂酸镁, puriss., meets analytical specification of Ph. Eur., BP, ≥90% stearic and palmitic acid basis, ≥40% stearic acid basis (GC), 4.0-5.0% Mg basis (calc on dry sub.)
甲基丙烯酸甲酯, European Pharmacopoeia (EP) Reference Standard
2-(二甲氨基)甲基丙烯酸乙酯, European Pharmacopoeia (EP) Reference Standard
甲基丙烯酸丁酯, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
柠檬酸三乙酯, Vetec, reagent grade, 98%